NCT04410692

Brief Summary

The goal of this study is to better understand how people predict the future risks of the novel Coronavirus (COVID-19). Specifically, the investigators will ask the following research questions:

  • How well do participants predict the future risks of COVID-19?
  • Can the predictions be improved by using a prediction market mechanism?
  • Does the prediction market reduce people's fear of COVID-19?

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
560

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started May 2020

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 15, 2020

Completed
1 day until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 16, 2020

Completed
1 day until next milestone

Study Completion

Last participant's last visit for all outcomes

May 17, 2020

Completed
10 days until next milestone

First Submitted

Initial submission to the registry

May 27, 2020

Completed
5 days until next milestone

First Posted

Study publicly available on registry

June 1, 2020

Completed
Last Updated

June 2, 2020

Status Verified

May 1, 2020

Enrollment Period

1 day

First QC Date

May 27, 2020

Last Update Submit

May 30, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • Predictions of COVID-19 Cases and Deaths

    Participants are asked 16 questions of the following format: "What do you think will be the total cumulative number of cases in Singapore on 8th of June, at 12pm?" Each question has 5 answer options. Each answer option is a range of possible outcomes. The primary outcome measure is participants' perceived likelihood of each answer option. The 16 questions come from the following variations: 4 countries (Mexico, Singapore, Turkey, USA) x 2 outcome measures (cases, deaths) x 2 time periods (8th of June, 6th of July).

    24 hours

Secondary Outcomes (1)

  • Fear

    24 hours (participants are required to submit post-experiment survey within 24 hours of completion of the main experiment)

Study Arms (2)

Control

NO INTERVENTION

Participants' COVID-19 predictions are elicited via a survey

Treatment

EXPERIMENTAL

Participants' COVID-19 predictions are elicited via a prediction market

Other: Prediction Market

Interventions

Participants "bet" on likely future outcomes using a prediction market

Treatment

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • National University of Singapore students

You may not qualify if:

  • N/A

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National University of Singapore

Singapore, Singapore

Location

Related Publications (1)

  • Camerer CF, Dreber A, Holzmeister F, Ho TH, Huber J, Johannesson M, Kirchler M, Nave G, Nosek BA, Pfeiffer T, Altmejd A, Buttrick N, Chan T, Chen Y, Forsell E, Gampa A, Heikensten E, Hummer L, Imai T, Isaksson S, Manfredi D, Rose J, Wagenmakers EJ, Wu H. Evaluating the replicability of social science experiments in Nature and Science between 2010 and 2015. Nat Hum Behav. 2018 Sep;2(9):637-644. doi: 10.1038/s41562-018-0399-z. Epub 2018 Aug 27.

    PMID: 31346273BACKGROUND

MeSH Terms

Conditions

Behavior

Study Officials

  • Teck Ho, PhD

    National University of Singapore

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Senior Deputy President & Provost

Study Record Dates

First Submitted

May 27, 2020

First Posted

June 1, 2020

Study Start

May 15, 2020

Primary Completion

May 16, 2020

Study Completion

May 17, 2020

Last Updated

June 2, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will share

Investigators will not be storing or sharing any personal identifiers. All individual level data will be anonymized, and only anonymized data will be shared with other researchers, upon request.

Shared Documents
STUDY PROTOCOL, ICF, ANALYTIC CODE
Time Frame
After completion of all analysis. It will be made available in the supporting documentation.
Access Criteria
It will be made available in the supporting documentation.

Locations